UBS Group
FLNA

UBS Group’s Filana Therapeutics FLNA Stock Holding History

UBS Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,000
Closed -$2.51M – 11084
2022
Q3 		$2.51M Buy
+60,000
New +$1.62M ﹤0.01% 2961
2021
Q4 		– Sell
-10,000
Closed -$621K – 10642
2021
Q3 		$621K Buy
+10,000
New +$835K ﹤0.01% 4573

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

UBS Group's FLNA Position: Q2 2026 in Review

UBS Group increased its Filana Therapeutics (FLNA) stake by 237% in Q2 2026, buying an estimated $39.1K and bringing the position to 39,062 shares worth $46.5K. The position accounts for ﹤0.01% of the portfolio, ranked #7611.

UBS Group first reported a position in FLNA in Q4 2014 and has held it in 47 quarters since. The position peaked at $2.62M in Q3 2024. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • UBS Group held 39,062 shares of Filana Therapeutics worth $46.5K as of Q2 2026.
  • UBS Group bought 27,459 Filana Therapeutics shares in Q2 2026, an estimated $39.1K.
  • Filana Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7611 holding.
  • UBS Group first reported a position in Filana Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Filana Therapeutics position peaked at $2.62M in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.